Galmed Pharmaceuticals Ltd GLMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
-
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
-
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
-
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
-
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Trading Information
- Previous Close Price
- $0.55
- Day Range
- $0.52–0.59
- 52-Week Range
- $0.41–2.30
- Bid/Ask
- $0.52 / $0.53
- Shares Outstanding
- 7.68M
- Market Cap
- $4.19M
- Volume/Avg
- 320,046 / 722,312
Key Statistics
- Price/Earnings (Normalized)
- 0.36
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.galmedpharma.com
Valuation
|
Metric
|
GLMD
|
|---|---|
Price/Earnings (Normalized) | 0.36 |
Price/Book Value | 0.26 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
GLMD
Financial Strength
|
Metric
|
GLMD
|
|---|---|
Quick Ratio | 7.65 |
Current Ratio | 7.71 |
Interest Coverage | — |
Quick Ratio
GLMD
Profitability
|
Metric
|
GLMD
|
|---|---|
Return on Assets (Normalized) | −40.05% |
Return on Equity (Normalized) | −45.45% |
Return on Invested Capital (Normalized) | −50.60% |
Return on Assets
GLMD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|&#>vx$? | LOCK|!c&h | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^kyj%l | LOCK|xtbk? | $71B | |||
| argenx SE ADR
ARGX
| LOCK|Rz>^z% | LOCK|m@s | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^?rT#G | LOCK|jXy | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<m#Jkkv | LOCK|$@wnB | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|T%<Zq^xN | LOCK|HCzf$ | $26B | |||
| Moderna Inc
MRNA
| LOCK|ZL#PCjM | LOCK|m^ | $25B | |||
| Incyte Corp
INCY
| LOCK|wh@HlS> | LOCK|QW | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|!t#@^r | LOCK|mD | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|rhL<d? | LOCK|>< | $16B |
United States